Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALN-4324 · 2 trials · 2 indications
M-value is measured as the glucose infusion rate at steady state
| Arm | Type | Description |
|---|---|---|
| ALN-4324 | EXPERIMENTAL | Participants will be administered a single dose of ALN-4324. |
| Placebo | PLACEBO_COMPARATOR | Participants will be administered a single dose of placebo. |
| Part A: ALN-4324 | EXPERIMENTAL | Participants will be administered a single dose of ALN-4324. |
| Part A: Placebo | PLACEBO_COMPARATOR | Participants will be administered a single dose of placebo. |
| Part B: ALN-4324 | EXPERIMENTAL | Participants will be administered multiple doses of ALN-4324 |
| Part B: Placebo | PLACEBO_COMPARATOR | Participants will be administered multiple doses of placebo |
| Name | Type | Description |
|---|---|---|
| ALN-4324 | DRUG | ALN-4324 will be administered subcutaneously (SC). |
| Placebo | DRUG | Placebo will be administered SC. |
Inclusion Criteria: * Is an adult patient with a confirmed diagnosis of T2DM * Has a body mass index (BMI) of ≥23 kg/m\^2 to ≤39.9 kg/m\^2 * Has a hemoglobin A1c (HbA1c) ≥6.5% to \<10.5% * Is on a stable dose of metformin, sodium-glucose cotransporter 2 inhibitor (SGLT2i), or dipeptidyl peptidase-4...
ALN-4324 is an investigational drug being developed for Type 2 Diabetes Mellitus (T2DM) and is also studied in obese or overweight healthy volunteers. It is in Phase 1 clinical development for these metabolic conditions.
ALN-4324 is being developed by Alnylam Pharmaceuticals, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol ALNY.
ALN-4324 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials.
ALN-4324 is being evaluated in a Phase 1 trial with the identifier NCT06845202. This study is active but not recruiting and enrolls overweight to obese healthy volunteers and patients with Type 2 Diabetes Mellitus.
Yes, ALN-4324 is being studied in patients with Type 2 Diabetes Mellitus (T2DM). The Phase 1 trial NCT06845202 includes overweight to obese patients with T2DM, and the study is being conducted in multiple countries.
The ALN-4324 Phase 1 trial, NCT06845202, is a randomized, double-blind, placebo-controlled study. It enrolls 105 participants who are overweight to obese healthy volunteers or patients with Type 2 Diabetes Mellitus.